Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ticagrelor

- PMLiVE

UK Biobank study to review human ageing over time moves into second stage

Over 60,000 volunteers to have second whole-body scans for imaging research study

- PMLiVE

AstraZeneca’s heart failure treatment recommended by NICE for expanded use

More than 550,000 patients have a confirmed heart failure diagnosis in England alone

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in US

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

- PMLiVE

AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer

Around 2.2 million people are diagnosed with lung cancer globally each year

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

AstraZeneca’s mild combination asthma reliever approved in UK

Over two and a half million adults with mild cases of asthma could be eligible for the treatment

- PMLiVE

AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer

More than 52,000 men are diagnosed with prostate cancer every year in the UK alone

- PMLiVE

AstraZeneca announces major expansion of Canadian research footprint

The investment includes the creation of 500 jobs and a new rare disease research hub

- PMLiVE

ABPI sets out proposals for UK government to support the NHS and economy

The association is suggesting a fixed rebate rate of 6.88% on all eligible UK drug sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links